To improve the oral absorption of meropenem (MEPM), we synthesized and evaluated a series of its double-promoiety prodrugs, in which lipophilic promoieties were introduced into carboxyl and pyrrolidinyl groups. Among these prodrugs, pivaloyloxymethyl (1R,5S,6S)-2-[(3S,5S)-5-(N,N-dimethylcarbamoyl)-1-(isobutyryloxymethyloxycarbonyl)pyrrolidin-3-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate (4) and 1-ethylpropyloxycarbonyloxymethyl (1R,5S,6S)-2-[(3S,5S)-5-(N,N-dimethylcarbamoyl)-1-(isobutyryloxymethyloxycarbonyl)pyrrolidin-3-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate (8) were chosen for further evaluation. Compounds 4 and 8 were well absorbed after oral administration to rats and beagles (bioavailability 18.2-38.4%), and expected to show potent therapeutic efficacy in patients infected with various pathogens, such as penicillin-resistant S. pneumoniae and b-lactamase-negative ampicillin-resistant H. influenzae. The Journal of Antibiotics (2011) 64, 233-242; doi:10.1038/ja.2010; published online 12 January 2011
INTRODUCTION
Carbapenems are the most potent class of b-lactam antibiotics, which have a broad spectrum of potent antibacterial activities against Grampositive and Gram-negative organisms, including P. aeruginosa. 1, 2 Carbapenems are stable to hydrolysis by various b-lactamase, and thus, effective against most cephalosporin-resistant microorganisms. [3] [4] [5] Imipenem, panipenem and meropenem (MEPM) have long been used for serious infectious diseases, including complicated urinary tract infection and complicated respiratory tract infection ( Figure 1 ). 1 Recently, doripenem has been launched as a new potent carbapenem ( Figure 1 ). 6 However, these are all for parenteral use only. Imipenem and panipenem are unstable chemically and to renal dehydropeptidase-I, and are thus used in combination with cilastatin and betamipron, respectively. MEPM and doripenem have a 1b-methyl group, and are stable against chemical degradation and hydrolysis by dehydropeptidase-I, [7] [8] [9] and are thus used without cilastatin or betamipron.
All these parenteral carbapenems have a carboxyl group at the carbapene C-3 position, which is essential for interaction with a target protein, penicillin-binding protein, 1 and a basic group at the pyrrolidine N-1 position, which promote their invasion through D2 porin into P. aeruginosa, 10 resulting in little oral absorption because of the two ionizable groups. Many attempts to find new orally active carbapenems have been reported, 11, 12 in which the basic group at the pyrrolidine N-1 position was eliminated and the carboxyl group was esterified by easily hydrolizable promoiety to increase oral absorption, but most showed very weak antibacterial activity against P. aeruginosa. Recently, tebipenem was developed in Japan and approved as a new orally active carbapenem ( Figure 1 ). Tebipenem showed potent activity against penicillin-resistant S. pneumoniae, b-lactamase-negative ampicillin-resistant H. influenzae, H. influenzae and E. coli; [13] [14] [15] however, unlike MEPM, tebipenem has no activity against b-lactamase-producing P. aeruginosa 2 and its therapeutic use is still limited to pediatric otitis media, rhinitis and pneumonia. In the present study, we attempted to increase the oral bioavailability of MEPM by chemical modification to a double-promoiety prodrug, because MEPM is chemically and biologically more stable than imipenem and panipenem, and has a lower molecular weight than doripenem. Furthermore, its efficacy in infection therapy and safety have been established. 16 We have reported the successful modification of ceftizoxime, a parenteral cephalosporin, to a double-promoiety prodrug with lipophilic and hydrophilic promoieties. 17, 18 Here, double-promoiety prodrugs of MEPM, in which two kinds of lipophilic promoieties were introduced at the carbapene C-3 and pyrrolidine N-1 position of MEPM to increase oral bioavailability, were synthesized and biologically evaluated.
Drug design
First, single-promoiety prodrugs of MEPM were designed using pivaloyloxymethyl (POM) and 1-ethylpropyloxycarbonyloxymethyl (EPC), as shown in Figure 2 . b-Lactam antibiotics, such as penicillins, cephalosporins and carbapenems, have a carboxyl group that decreases their membrane permeability, resulting in low oral absorption. In many orally used penicillins and cephalosporins, their carboxyl group is esterified with a lipophilic and hydrolyzable promoiety: these prodrugs are efficiently absorbed and then rapidly hydrolyzed to an active form. As such a promoiety, POM is used in pivmecillinam, cefteram, cefetamet, cefditoren and cefcapene; however, a POM promoiety in cephalosporins has been reported to decrease plasma carnitine levels in children. 19 As a non-POM promoiety, carbonate-type promoieties have been used: 1-(cyclohexyloxycarbonyloxy)ethyl and 1-(isopropyloxycarbonyloxy)ethyl in cefotiam and cefpodoxime, respectively, both racemic promoieties. Here, we chose EPC without an asymmetric carbon as a non-POM promoiety for a prodrug.
Second, double-promoiety prodrugs of MEPM were designed by introduction of the second lipophilic promoiety to the pyrrolidine N-1 position of MEPM ( Figure 2 ) because no single-promoiety prodrugs of parenteral carbapenems have been successfully developed, probably due to their basic side chain, which is also considered to decrease their membrane permeability. As the second lipophilic promoiety, carbonate promoieties (isobutyryloxymethyloxycarbonyl, propionyloxymethyloxycarbonyl, butyryloxymethyloxycarbonyl and valeryloxymethyloxycarbonyl) were used.
Chemistry
The general synthetic routes of prodrugs of MEPM are shown in Scheme 1. All prodrugs were prepared from MEPM. Singlepromoiety prodrugs 1 and 2 were prepared by esterification with the corresponding alkyl iodides, and 3 was afforded by Nalkylation of pyrrolidine moiety. 20 Double-promoiety prodrugs 4-10 were prepared by N-alkylation and esterification in one pot, as described above.
Other synthetic routes of compounds 4 and 8 are shown in Scheme 2-4. In Scheme 2, introduction of 1-isobutyryloxymethyl (2S,4S)-2-N, N-dimethylcarbamoyl-4-mercaptopyrrolidine-1-carboxylate (BMP) 21 to p-nitrobenzyl (1R,5S,6S)-2-diphenylphosphoryl-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate (MAP) at the carbapene C-2 position was achieved to give 11 in accordance with the literature. 22 p-Nitrobenzyl moiety of 11 was removed by Pd-C catalyzed hydrogenation to yield a carboxylic acid derivative, which was esterified with POM-I and EPC-I in the presence of benzyl triethylammonium chloride (BTEAC) to give compounds 4 and 8, respectively.
In Scheme 3, compound 4 was prepared from (3S,4S)-
The b-MAC was esterified with a magnesium salt of POMesterified malonate using 1,1¢-carbonyldiimidazole (CDI) as a condensing reagent to give 12. Compound 12 was treated with p-dodecylbenzenesulfonyl azide to give a-diazoester 13, which was then cyclized with rhodium catalyst, and the product was phosphorylated to give 14. 22 Compound 14 was treated with BMP to give 15, from which the tert-butyldimethylsilyl (TBS) group was removed by Et 3 NÁ3HF to give 4.
In Scheme 4, the carboxyl moiety of b-MAC was converted to thioester of BMP using 1-ethyl-3-(dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-methylmorpholine to give 16. Acylation of 16 with EPC ester of oxalic acid afforded 17, which was reacted with Prodrug of meropenem S Tanaka et al diethoxymethyl phosphine in toluene, and cyclized by heat to give 18. Finally, the TBS group of 18 was removed to give 8, as described in Scheme 3. Introduction of a second lipophilic promoiety to the pyrrolidine N-1 position increased logD to 1.53-2.68 and decreased water solubility to 51.8-846.5 mg ml À1 (4-8). Double-promoiety prodrugs with POM (4-7) showed similar Cmax and bioavailability. Compound 4 was chosen for further evaluation among compounds 4-7 as it was most stable in the preliminary stability test, in which the solid compounds were kept at 40 1C in a tightly capped glass bottle with silica gel for 2 weeks followed by determination of their purity. A double-promoiety prodrug with EPC (8) showed slightly lower Cmax and bioavailability than those of POM-type double-promoiety prodrugs. To further increase its Cmax and bioavailability, racemic promoieties 1-(cyclohexyloxycarbonyloxy)ethyl and 1-(isopropyloxycarbonyloxy)ethyl were introduced (9 and 10); however, little changed in 9 and rather decreased in 10. Compound 9, but not 8 was unstable in the preliminary stability test. Compound 8 was also chosen for further evaluation as a non-POM doublepromoiety prodrug.
RESULTS

Physicochemical
Pharmacokinetics of compounds 4 and 8 in rats and beagles
In male rats, the pharmacokinetics of MEPM after oral administration of compounds 4 and 8 was reevaluated to more precisely determine the parameters: blood was taken at 10, 20, 30, 45, 60, 90 and 120 min after administration. The Cmax was similar between compounds 4 and 8, and AUC and bioavailability were slightly higher and T 1/2 was longer in compound 4 than 8 ( Figure 3 , Table 2 ). It was confirmed that oral absorption of MEPM was effectively increased in the double-promoiety prodrugs in comparison with the corresponding single-promoiety prodrugs (4 vs 1 and 8 vs 2).
In male beagles, the pharmacokinetics of compounds 4 and 8 were evaluated ( Figure 4 , Table 3 ). The Cmax was similar between compounds 4 and 8, and AUC and bioavailability were higher and T 1/2 was longer in compound 4 than 8.
DISCUSSION
MEPM has potent and broad antibacterial activities, and has long been used clinically. Its efficacy and safety have been established, and thus, it is still a useful parenteral antibiotic. 16 Development of orally active carbapenems has been desired because of the increase of microorganisms resistant to oral antibacterial agents, such as cephalosporin and fluoroquinolone; however, it is difficult to improve the oral absorption of parenteral carbapenems by conventional prodrug methods used in cephalosporin, such as cefuroxime, 23 in which a carboxyl group was esterified, because carbapenems are chemically and biologically less stable than cephalosporins. Furthermore, their basic group, which is essential for anti-bacterial activities against P. aeruginosa, 10 is also considered to limit their oral absorption. Although some newly synthesized chemically and biologically stable carbapenems lacking a basic group were reported, 11, 12 no compounds have been successfully developed. Recently, tebipenem, showing high bioavailability and high activity against penicillinresistant S. pneumoniae and b-lactamase-negative ampicillin-resistant H. influenzae, was approved in Japan for pediatric otitis media, rhinitis 
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S Tanaka et al and pneumonia. [13] [14] [15] In the present study, we attempted to apply our double-promoiety prodrug method to MEPM to increase its bioavailability. We succeeded in modifying ceftizoxime, a parenteral cephalosporin, to orally bioavailable double-promoiety prodrugs, in which the appropriate balance of lipophilicity and hydrophilicity was achieved by the introduction of both lipophilic promoiety and hydrophilic promoiety. 17, 18 In MEPM, conventional esterification of the carboxyl group is not enough to achieve appropriate lipophilicity because of the presence of a basic group. Indeed, compound 1 with POM and compound 2 with EPC at the carbapene C-3 position still had low lipophilicity and were highly water soluble, and thus their oral absorption was little or only slightly increased. However, in addition, introduction of a second lipophilic group, which is known to be hydrolyzable and useful in promoieties, at the pyrrolidine N-1 position increased lipophilicity and decreased water solubility, and markedly enhanced Cmax and AUC compared with the corresponding single-promoiety prodrugs. Among them, compounds 4 and 8 showed similar Cmax in rats and beagles (0.96-2.92 mg ml À1 ), which were higher than the minimum inhibitory concentration of MEPM against penicillin-resistant S. pneumoniae, H. influenzae and E. coli. Their bioavailabilities in animals are relatively low compared with clinically used cephalosporins; however, double-promoiety prodrugs including ceftizoxime alapivoxil, showed higher urinary recovery in humans than rats or beagles (more than twofold). 17, 24 Compounds 4 and 8 are also expected to show higher bioavailability in humans than animals, and to show potent anti-infection effects in patients. Indeed, the dosage regimen of compound 8 in mice for the simulation of the predicted human pharmacokinetics significantly reduced viable cell counts in the lungs of mice intranasally infected with three strains of drug-resistant S. pneumoniae. 25 Whereas compound 4 showed longer T 1/2 than 8, the POM moiety of 4 might decrease plasma carnitine levels in children, as reported previously for cephalosporins. 19 To select a candidate for clinical study, further study is needed to precisely determine their pharmacokinetic properties, safety and therapeutic efficacy in various infectious models, including respiratory tract infection and urinary tract infection models. Compounds 4 and 8 would be the first orally active carbapenems effective against P. aeruginosa, derived from a parenteral antibiotic, which could be also useful in switch therapy from injection of MEPM to oral administration.
In conclusion, MEPM was successfully modified to double-promoiety prodrugs with excellent oral absorption by the introduction of two lipophilic promoieties on two sides. This method is thought to be applicable to other small parenteral drugs with low oral absorption because of two or more ionizable promoieties.
EXPERIMENTAL PROCEDURE General procedure
Chemicals were obtained from commercial sources and used without purification. Reactions were monitored by TLC on Merck precoated silica gel 60 F 254 (0.25 mm, Merck, Darmstadt, Germany) plates. The spots on TLC were visualized by UV light (254 nm), iodine and ninhydrin. Column chromatography was performed on silica gel (Daisogel NO.1001W; Daiso, Osaka, Japan) or HP-21 (Diaion; Mitsubishi Chemical, Tokyo, Japan). Melting points were measured on a melting point apparatus (MP-21; Yamato Scientific, Tokyo, Japan) and are uncorrected. IR spectra were obtained with an infrared spectrometer (FT-720; HORIBA, Kyoto, Japan or FT-IR8200PC; Shimadzu, Kyoto, Japan). 1 H-NMR spectra were recorded at 400 MHz (JNM-AL400; JEOL, Tokyo, Japan) or 90 MHz (Hitachi FT-NMR R-1900; Hitachi HighTechnologies, Tokyo, Japan) on a nuclear magnetic resonance spectrometer using tetramethylsilane as an internal standard. Mass spectra (MS) were obtained on a QTRAP LC/MS/MS system (API2000; Applied Biosystems, Foster City, CA, USA). 
Synthetic procedures in Scheme 1
Sodium (1R,5S,6S)-2-[(3S,5S)-5-(N,N-
Dimethylcarbamoyl)-1-(isobutyryloxymethyl- oxycarbonyl)pyrrolidin-3-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3- carboxylate (3).
Pivaloyloxymethyl (1R,5S,6S)-2-[(3S,5S)-5-(N,N-
. To a suspension of MEPM (17.4 g, 45.5 mmol) in DMF (70 ml) at 0 1C was added isobutyryloxymethyl p-nitrophenyl carbonate (15.0 g, 50.1 mmol), and the mixture was stirred at room temperature for 1 h, followed by the addition of pivaloyloxymethyl iodide (30.6 g, 114 mmol) at 0 1C, and stirring at room temperature for 2 h. After the addition of 5% NaHCO 3 aq. (150 ml), the mixture was extracted with EtOAc (200 ml), and then the organic layer was washed with 5% NaHCO 3 aq. and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography (silica gel, n-hexane-EtOAc) to give a solid (16.5 g 
. A solution of 11 (1.00 g, 1.51 mmol) in THF-0.1 M MOPS buffer (pH 7.0) (1:1) (100 ml) was hydrogenated at 3 kg cm À2 in the presence of 10% Pd-C (250 mg) at 35 1C for 1h. After removal of the catalyst by filtration, the filtrate was extracted with 0.1 M MOPS buffer (pH 7.0) (30 ml), and then, THF was evaporated under reduced pressure. The aqueous residue was washed with EtOAc, and evaporated under reduced pressure. To a solution of the residue in CH 2 Cl 2 (10 ml) were added BTEAC (100 mg, 0.44 mmol) and pivaloyloxymethyl iodide (548 mg, 2.26 mmol), and the mixture was stirred at room temperature overnight. After evaporation of the mixture under reduced pressure, the solution of the residue in EtOAc (100 ml) was washed with water (50 ml) and 5% NaCl aq., dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography (silica gel, EtOAc-acetone) to give an oil (1.1 g). To the solution of the oil in EtOAc (2.2 ml) was added i-Pr 2 O (5.0 ml), and the mixture was stirred at room temperature overnight. The resulting precipitate was collected by filtration to give 4 (803 mg, 83% yield) as a white solid.
Compound 8 was obtained as a white solid (833 mg, 82% yield) from 11 (1.00 g, 1.51 mmol) in a similar manner to that described in the synthesis of 4.
Synthetic procedures in Scheme 3 (14) . To a solution of 13 (440 mg, 0.91 mmol) in EtOAc (3.5 ml) at 50 1C was added [(AcO) 2 Rh] 2 Á2H 2 O (22 mg, 0.05 mmol), and the mixture was stirred for 20 min, and then evaporated under reduced pressure. To a solution of the residue in CH 3 CN (4 ml) at 0 1C were added diphenyl chlorophosphate (0.21 ml, 1.0 mmol) and i-Pr 2 NEt (0.17 ml, 0.98 mmol), and then the mixture was stirred at the same temperature for 40 min. After the addition of EtOAc, the mixture was washed with water and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography (silica gel, n-hexane-EtOAc) to give 14 (480 mg, 77% yield) as an oil. 1 (4) . To a solution of 15 (70 mg, 0.093 mmol) in DMF (0.7 ml) was added Et 3 NÁ3HF (30 mg, 0.9 mmol), and the mixture was stirred at room temperature for 23 h. After the addition of EtOAc, the mixture was washed with 5% NaCl aq. and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. To a solution of the residue in EtOAc (0.5 ml) at 0 1C was added i-Pr 2 O (1.0 ml), and the mixture was stirred for 2 h. The resulting precipitate was collected by filtration to give 4 (10 mg, 17% yield) as a white solid. and BMP (6.38 g, 20.0 mmol) in DMF (25 ml) at 0 1C were added EDC (6.40 g, 33.4 mmol) and N-methylmorpholine (3.67 ml, 33.4 mmol) at 0 1C, and the mixture was stirred at room temperature for 1 h. After the addition of EtOAc, the mixture was washed with water and brine, dried over Na 2 SO 4 , and evaporated under reduced pressure. The residue was purified by column chromatography (silica gel, n-hexane-EtOAc) to give 16 (7.18 g, 71% yield) as an oil. 1 
Synthetic Procedures in Scheme 4
